Questions we’re asking about donanemab (Kisunla)

Asking challenging questions is essential when developing and commercializing new medicines.

Whether you’re a doctor, patient, payer, or working commercially, challenging the status quo and going beyond what you are told is essential.

Alzheimer’s is an area I have worked in for a long time and continue to follow. Here are a few of the questions I’m interested in following the approval of donanemab in a second major market.

Note: Use the arrows at the bottom of the PDF to scroll through the pages.